Skip to main content
SpringerLink
Log in

Analysis of neovasculature in uveal melanoma by targeting the TGFβ-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Endoglin/CD105 is a transmembrane regulatory receptor for transforming growth factor-β (TGF-β) that is predominantly expressed on proliferating endothelial cells (ECs) in culture and on angiogenic blood vessels in vivo. Endoglin has been associated with angiogenesis and prognosis in several malignancies. Although microvascular structure has been characterized by a variety of different other endothelial markers so far, there is no consensus on the prognostic value of microvessel quantification in uveal melanoma due to differences in tissue pretreatment, variability in the reactivity of endothelial cell markers, blood vessel counting methods, and vasculogenic mimicry by melanoma cells expressing endothelial cell markers. The aim of this study was to investigate the expression pattern of endoglin and to evaluate whether proliferative activity of ECs determines the clinical prognosis of uveal melanoma.

Methods

Paraffin sections from 35 clinicopathologically well-characterized cases of primary uveal melanomas were stained for Ki-67, von Willebrand factor (vWF) and endoglin. In 16 cases, metastatic disease led to death. The mean follow-up of the nonmetastasized cases was 10.6 (9–13) years. The immunohistological specimens were evaluated by three independent observers who were masked to the follow-up of patients. Statistical analyzes included Kaplan-Meier survival curves and the fitting of log-rank and Wilcoxon test models.

Results

Immunohistochemistry with vWF confirmed that all examined specimens were vascularized. Expression of Ki-67 could be found in 26 (74%) of the samples. Moderate to high expression of endoglin was found in 13 cases (37%). Kaplan-Meier analysis showed a significant association (p<0.001) between an enhanced endoglin expression and death due to metastatic uveal melanoma.

Conclusions

The study demonstrates for the first time that the expression of endoglin can be used as a specific marker for angiogenesis in uveal melanomas. Thus, differentiation between the quiescent and proliferating ECs enables the location and characterization of hot spots of angiogenesis in melanomas. The data suggest not only a prognostic relevance in individual patients but promise applications in assessing the efficacy of antiangiogenic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Altamente M, Montagner R, Fonsatti E, Coalizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M (1996) Expression and structural features of endoglin (CD105), a transforming growth factor b1 and b3 binding protein, in human melanoma. Br J Cancer 74:1586–1591

    PubMed  Google Scholar 

  2. Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 274:584–594

    Article  PubMed  CAS  Google Scholar 

  3. Barbareschi M, Weidner N, Gasparini G, Morelli L, Forti S, Eccher C, Fina P, Caffo O, Leopardi E, Mari F, Bevilacqua P, Dalla Palma P (1995) Appl Immunochem 3:75–84

    Google Scholar 

  4. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (1998) Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 18:2701–2710

    PubMed  CAS  Google Scholar 

  5. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761

    Article  PubMed  CAS  Google Scholar 

  6. Buhring HJ, Muller CA, Letarte M, Gougos A, Saalmuller A, van Agthoven AJ, Busch FW (1991) Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5:841–847

    PubMed  CAS  Google Scholar 

  7. Chang YS, Di Tomaso E, McDonald EM, Jones R, Jain RK, Munn LL (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci 97:14608–14613

    Article  PubMed  CAS  Google Scholar 

  8. Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R (2002) Uveal melanoma cell staining for CD34 and assessment of tumour vascularity. Investig Ophthalmol Vis Sci 43:2533–2539

    Google Scholar 

  9. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C (2004) Prediction of metastasis risk using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer. Br J Cancer 90:1216–1221

    Article  PubMed  CAS  Google Scholar 

  10. Dawn G, MacKie RM (2002) Expression of endoglin in human melanocytic lesion. Clin Exp Derm 27:153–156

    Article  PubMed  CAS  Google Scholar 

  11. Derbyshire E, Thrope P (1997) Targeting the tumour endothelium using specific antibodies. In: Bicknell R, Lewis C, Ferrara N (eds) Tumour angiogenesis. Oxford University Press, Oxford, pp 343–356

    Google Scholar 

  12. Derrynk R, Feng XH (1997) TGF-beta receptor signaling. Biochim Biophys Acta 1333:105–150

    Google Scholar 

  13. Edel M, Robbins P, D'Antuono M, Harvey J, Papadimitrion J, Mitchell C, Dawkins H (2000) Assessment of endothelial cell proliferation in primary breast carcinoma and its association with axillary lymph node status. Breast 9:28–34

    Article  PubMed  CAS  Google Scholar 

  14. Fleiss JL (1971) Measuring scale agreement among many raters. Psychol Bull 76:378–382

    Article  Google Scholar 

  15. Folberg R, Rummelt V, Parys-van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM (1993) The prognostic value of tumour blood vessel morphology in primary uveal melanoma. Ophthalmol 1993:1389–1398

    Google Scholar 

  16. Folberg R (1997) Discussion of paper by Foss et al. Br J Ophthalmol 81:247–248

    Google Scholar 

  17. Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112:508–525

    Article  PubMed  Google Scholar 

  18. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  19. Fonsatti E, Maio M (2004) Highlights on endoglin (CD105); form basic findings towards clinical applications in human cancer. J Transl Med 2:18–24

    Article  PubMed  Google Scholar 

  20. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S (1996) Microvessel count predicts survival in uveal melanoma. Cancer Res 56:2900–2903

    PubMed  CAS  Google Scholar 

  21. Fox SB, Harris AL (2004) Histological quantification of tumour angiogenesis. APMIS 112:413–430

    Article  PubMed  Google Scholar 

  22. Gougos A, Letarte M (1988) Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141:1925–1933

    PubMed  CAS  Google Scholar 

  23. Gougos A, LeTarte M (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265:8361–8364

    PubMed  CAS  Google Scholar 

  24. Griffioen AW, Damen CA, Blijham GH, Groenewegen G (1996) Endoglin/CD105 may not be an optional tumour endothelial treatment target. Breast Cancer Res Treat 39:239–240

    Article  PubMed  CAS  Google Scholar 

  25. Grisanti S, Canbek S, Kaiserling E, Adam A, Lafaut B, Gelisken F, Szurman P, Henke-Fahle S, Oficjalska-Mlynczak J, Bartz-Schmidt KU (2004) Expression of endoglin in choroidal neovascularization. Exp Eye Res 78:207–213

    Article  PubMed  CAS  Google Scholar 

  26. Hoang MP, Selim MA, Bentley RC, Burchette JL, Shea CR (2001) CD34 expression in desmoplastic melanoma. J Cutan Pathol 28:508–512

    Article  PubMed  CAS  Google Scholar 

  27. Kumar S, Wang JM, Bernabeu C (1996) CD 105 and angiogenesis. J Pathol 178:363–366

    Article  PubMed  CAS  Google Scholar 

  28. Letarte M, Greaves A, Vera S (1995) CD105 (endoglin). In: Schlossman SF, Baumsell L, Gilks W (eds) Leukocyte typing. Oxford University Press, Oxford, pp. 1756–1759

    Google Scholar 

  29. Lane AM, Egan KM, Yang J, Saornil MA, Alroy J, Albert D, Gragoudas ES (1997) An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res 7:237–242

    Article  PubMed  CAS  Google Scholar 

  30. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S (2003) Both high intratumoural microvessel density determined using CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88:1424–1431

    Article  PubMed  CAS  Google Scholar 

  31. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T (1999) Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Investig Ophthalmol Vis Sci 40:2471–2480

    Google Scholar 

  32. McDonald DM, Munn L, Jain RK (2000) Vasculogenic mimicry: how convincing, how novel and how significant? Am J Pathol 156:383–388

    PubMed  CAS  Google Scholar 

  33. Pezzella F (2000) Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet 355:17878

    Google Scholar 

  34. Risau W (1995) Differentiation of endothelium. FASEB J 9:926–933

    PubMed  CAS  Google Scholar 

  35. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA (2003) Significance of CD105 expression for tumour Angiogenesis and prognosis in endometrial carcinoma. APMIS 111:1011–1018

    Article  PubMed  Google Scholar 

  36. Schaling DF, Van der Pol JP, Schlingemann RO, Parys-van Ginderdeuren R et al (1999) Vascular density and vascular patterns in the prognosis of choroidal melanoma. In: Schaling DF (ed) Radionuclides and radiolabeled antibodies in choroidal melanoma (diagnosis and therapy). Rijksuniversiteit te Leiden, Leiden, pp. 43–54

    Google Scholar 

  37. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor REB, Hendrix MJC (2002) Expression of multiple molecular phenotypes by aggressive melanoma tumour cells: role in vasculogenic mimicry. Crit Rev Onc 44:17–27

    Article  Google Scholar 

  38. Seon BK, Matsuno F, Haruta Y, Kondo M, Bareas M (1997) Long-lasting complete inhibition of human solid tumours in SCID mice by targeting endothelial cells of tumour vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031–1044

    PubMed  CAS  Google Scholar 

  39. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H (2001) Evaluation of Angiogenesis in non-small cell lung-cancer: comparison between anti-CD34 antibody and anti-CD 105 antibody. Clin Cancer Res 7:3410–3415

    PubMed  CAS  Google Scholar 

  40. Thorpe PE, Burrows FJ (1995) Antibody-directed targeting of the vasculature of solid tumours. Breast Cancer Res Treat 36:237–251

    Article  PubMed  CAS  Google Scholar 

  41. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268–275

    Article  PubMed  CAS  Google Scholar 

  42. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J (1994). Mechanism of activation of the TGF-β receptor. Nature 370:341–347

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology I, Eberhard-Karls University Tuebingen, Tuebingen, Germany

    Focke Ziemssen, Rayime Wegner, Jürgen Wegner, Olcay Tatar, Daniela Süsskind, Faik Gelisken, Martin Rohrbach, Karl U. Bartz-Schmidt & Salvatore Grisanti

  2. University Eye Hospital of Tuebingen, Dep. I, Schleichstrasse 12-15, 72076, Tuebingen, Germany

    Salvatore Grisanti

Authors
  1. Focke Ziemssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rayime Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olcay Tatar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniela Süsskind
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Faik Gelisken
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martin Rohrbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karl U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Salvatore Grisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvatore Grisanti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziemssen, F., Wegner, R., Wegner, J. et al. Analysis of neovasculature in uveal melanoma by targeting the TGFβ-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?. Graefe's Arch Clin Exp Ophthalmo 244, 1124–1131 (2006). https://doi.org/10.1007/s00417-005-0135-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-005-0135-z

Keywords

Search

Navigation